Background: The literature published about osteoid osteoma (OO) in the ankle-foot consists mainly on case reports.
Methods: We performed a retrospective study in which we analyzed demographic parameters, pain characteristics, treatment options and functional outcomes measured using the AOFAS and the SEFAS scales.
Results: We treated 17 patients with OO around the ankle-foot. Eighty-eight percent of patients had night pain that was relieved with NSAIDs. The bones most often affected were the talus and calcaneus. OO was diagnosed 21 months after the onset of symptoms. Mean follow-up was 17.3 years. The surgical techniques most used were curettage and curettage and bone grafting. There was a significant increase in AOFAS and SEFAS scores after surgery.
Conclusions: Suspicion is the base of a prompt and a correct diagnosis of OO. The OO should be especially suspected in patients who present night pain that can be relieved with NSAIDs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.fas.2020.03.012 | DOI Listing |
Int J Surg Pathol
January 2025
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Osteoid osteoma is a benign bone tumor commonly affecting young individuals, with a rare occurrence in older adults. It typically presents with night pain relieved by nonsteroidal anti-inflammatory drugs and is characterized radiographically by a small, radiolucent nidus surrounded by reactive sclerosis. We present a 70-year-old female patient with persistent right hip pain, initially diagnosed as arthritis, who underwent total hip arthroplasty.
View Article and Find Full Text PDFInt J Surg Case Rep
January 2025
Bone and Joint Diseases Research Center, Department of Orthopedic Surgery, Shiraz University of Medical Sciences, Iran; Golestan Rhematology Research Center, Golestan University of Medical Sciences, Gorgan, Iran. Electronic address:
Introduction And Importance: Osteoid osteoma (OO) is a common benign bone tumor, mostly affecting young adults. Since it often develops in long bones, OO is rarely considered as a cause of chronic shoulder pain.
Case Presentation: We treated an 8-year-old boy with ongoing shoulder pain that was worse at night but improved with NSAIDs.
Eur J Radiol
December 2024
Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, D-81377 Munich, Germany.
Objectives: To evaluate the influence of clinical and procedural factors, particularly the thickness of reactive sclerosis, on clinical outcome of MR-guided high-intensity focused ultrasound (MR-HIFU) for the treatment of symptomatic osteoid osteomas (OO) of the extremities.
Materials And Methods: 18 consecutive patients (median age 19.5y) with symptomatic OO of the extremities eligible for MR-HIFU were enrolled in this ongoing prospective study (German Clinical Trials Register; nr.
Radiol Case Rep
February 2025
Loyola University Medical Center and Loyola University Chicago, 2160 S First Ave, Maywood, IL 60153, USA.
Osteoid osteoma (OO), a benign bone-forming tumor estimated to account for 3% of all primary bone tumors, rarely occurs in the finger. This case report presents an unusual instance of osteoid osteoma in the finger of a 15-year-old male patient. The lesion was discovered following an initial patient visit for left middle finger pain and swelling for one year without any identifiable injuries.
View Article and Find Full Text PDFChilds Nerv Syst
December 2024
Departement of Pediatric Neurosurgery, Hôpital Femme Mère Enfant, Lyon, France.
Background And Aim: Osteoid osteoma (Oo) and osteoblastoma (Ob) are rare primary bone tumors with a higher prevalence in the second decade of life. Treatment can be conservative, but in cases of spinal location, resective surgery is of great importance but may be challenging.
Material And Methods: We report four pediatric cases of Oo and Ob managed in our unit, with different locations at the level of the cervical spine.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!